SEC Form 4 · accession 0001437749-26-025929
Moleculin Biotech, Inc. · MBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan P. Foster
Officer — Chief Financial Officer
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 4:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001659617
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2026 | P$0 | 293,333 | — | A | 305,673 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series I WarrantsF1 | — | Aug 3, 2026 | P | 879,999 | A | Aug 3, 2026 | Aug 3, 2031 | Common Stock | 879,999 | 1,027,717 | D |
Explanation of responses
- F1On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.